What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis

Journal of Parkinson's Disease
Dilan AthaudaThomas Foltynie

Abstract

Exenatide is a GLP-1 receptor agonist that was recently studied for potential disease-modifying effects in a randomised, placebo-controlled clinical trial in patients with moderate stage Parkinson's disease, and showed positive effects on the motor severity of the disease which were sustained 12 weeks beyond the period of exenatide exposure. Analysis of pre-defined secondary outcomes revealed no statistically significant differences between patients treated with exenatide in total non-motor symptom burden and overall quality of life measures. The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms. Compared to placebo, patients treated with exenatide-once weekly had greater improvements in individual domains assessing mood/depression across all observer-rated outcome measures after 48 weeks including the "mood/apathy" domain of the NMSS, - 3.3 points (95% CI - 6.2, - 0.4), p = 0.026; the "mood" score (Q1.3+Q1.4 of the MDS-UPDRS Part 1), - 0.3 points (95% CI - 0.6, - 0.1), p = 0.034; and a trend in the MADRS total score, - 1.7 points (95% CI - 3.6, 0.2), p = 0.071. In a...Continue Reading

References

Nov 20, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyRobert Trafficante
Feb 21, 2006·Lancet Neurology·K Ray ChaudhuriUNKNOWN National Institute for Clinical Excellence
Mar 21, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriCharles W Olanow
Aug 4, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriAnthony H V Schapira
Feb 16, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Claudia TrenkwalderUNKNOWN Recover Study Group
Sep 15, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·David A GallagherAnette Schrag
Apr 24, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P Martinez-MartinC G Goetz
Jun 4, 2013·The Journal of Clinical Investigation·Iciar Aviles-OlmosThomas Foltynie
Nov 6, 2013·Current Neurology and Neuroscience Reports·Laura Marsh
Mar 26, 2014·Journal of Parkinson's Disease·Iciar Aviles-OlmosThomas Foltynie
Apr 9, 2014·Parkinsonism & Related Disorders·Eva PirogovskyJ Vincent Filoteo
Jul 1, 2014·Current Opinion in Neurology·Jennifer G Goldman, Ron Postuma
Nov 11, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Pablo Martinez-MartinK Ray Chaudhuri
Apr 22, 2015·Lancet Neurology·Javier PagonabarragaPaul Krack
Jul 15, 2015·PloS One·Erika F AugustineOksana Suchowersky
Aug 13, 2015·Journal of Neural Transmission·Alexander StorchGeorg Ebersbach
Sep 24, 2015·Journal of Geriatric Psychiatry and Neurology·Tharini KetharanathanVaruni Asanka de Silva
Jan 3, 2016·Psychoneuroendocrinology·Rozita H AnderbergKarolina P Skibicka

❮ Previous
Next ❯

Citations

Aug 2, 2018·CNS Drugs·Dilan Athauda, Thomas Foltynie
Aug 3, 2018·The European Journal of Neuroscience·Dilan AthaudaThomas Foltynie
Oct 1, 2018·The European Journal of Neuroscience·Patrik Brundin, Richard K Wyse
May 29, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Jared T HinkleTed M Dawson
Jul 24, 2020·The Cochrane Database of Systematic Reviews·Caroline A MulvaneyHedley Ca Emsley
Jan 18, 2019·Nature Reviews. Neurology·Günther Deuschl, Rob M A de Bie
Nov 5, 2019·Frontiers in Neuroscience·Maddalena GriecoTiziana Filardi
Jul 28, 2020·Biomolecules·Joséphine ZangariJean-Claude Martinou
Jul 11, 2018·Nature Medicine·Lena BrundinPatrik Brundin
Apr 4, 2019·Frontiers in Neurology·Marie Therese Fuzzati-ArmenteroFabio Blandini
Apr 13, 2021·Frontiers in Neuroendocrinology·Carmen M LabandeiraAna I Rodriguez-Perez
Apr 27, 2021·Expert Opinion on Investigational Drugs·Evans D PopeMarwan Noel Sabbagh
Aug 10, 2019·ACS Pharmacology & Translational Science·Elliot J GlotfeltyNigel H Greig
Jan 13, 2022·Neural Regeneration Research·Carmen M LabandeiraAna I Rodriguez-Perez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.